Roth MKM sets a USD 3.00 target for Rapid Micro Biosystems stock

Published on 10/16/2026 at 00:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roth MKM starts coverage with a USD 3.00 target. A USD 9.88 million Q3 estimate for November 6, 2026 frames Rapid Micro Biosystems stock.

Coverage and operating milestones

Roth MKM initiated coverage with a USD 3.00 target on September 29, 2026.
Second-quarter revenue reached USD 8.10 million, up 11.00 percent year over year.
Rapid Micro Biosystems had a USD 38.6 million market capitalization as of October 15, 2026.

RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems (ISIN US75340L1044) drew a new analyst target of USD 3.00 from Roth MKM on September 29, 2026. The target accompanied a Buy rating, while the company entered the next reporting cycle with second-quarter revenue of USD 8.10 million.

Roth MKM sees room for expansion

According to Investing.com on September 29, 2026, Roth MKM initiated coverage with a Buy rating and a USD 3.00 price target. The same report put the company's second-quarter gross margin at 15.00 percent and said Rapid Micro Biosystems had installed about 200 systems.

The target is tied to a business that automates microbial quality-control testing for pharmaceutical manufacturing. The company says its Growth Direct platform replaces manual laboratory workflows with automated testing and data management. Its investor-relations page describes applications across biologics, vaccines, cell and gene therapies, and sterile injectables.

What does the next report require?

Rapid Micro Biosystems reported second-quarter revenue of USD 8.10 million, an 11.00 percent increase from the year-earlier quarter, according to Rapid Micro Biosystems. The release also highlighted the placement of the 200th Growth Direct system globally and four system placements during the quarter.

MarketBeat estimates third-quarter results for November 6, 2026, before the market opens. Its consensus calls for revenue of USD 9.88 million and adjusted earnings per share of minus USD 0.20, compared with USD 7.84 million and minus USD 0.26 in the year-earlier quarter.

Market value and investor dates

Rapid Micro Biosystems had a market capitalization of USD 38.6 million as of October 15, 2026. Its 52-week range was USD 0.81 to USD 4.94 on the same date, placing the company firmly in the small-cap segment.

For investors, the next report combines an operating test with a valuation test. Revenue must approach the USD 9.88 million consensus, while the 15.00 percent second-quarter gross margin gives the upcoming release a clear profitability benchmark.

Rapid Micro Biosystems stock and upcoming results

The company is listed on Nasdaq under ticker RPID and operates in the healthcare sector, with medical devices as its industry classification. The November 6, 2026 reporting date and the USD 3.00 analyst target are the two clearest reference points for the next phase of coverage.